Cowen & Co. Maintains a Buy Rating on Trillium Therpeutc (TR)
According to The Fly, in a new note to investors yesterday, an analyst has provided a rating update for the Healthcare company, Trillium Therpeutc (TR). The company recieved Buy from Cowen & Co.’s analyst Boris Peaker.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.8% and a 43.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Read also: Does Amarin’s (AMRN) Impending FDA Decision Matter?
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trillium Therpeutc.
Based on Trillium Therpeutc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$13.05 million. In comparison, last year the company had a GAAP net loss of C$11.34 million.
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.
The company’s shares closed on Monday at C$0.18.